Form 8-K - Current report:
SEC Accession No. 0001654954-25-007104
Filing Date
2025-06-17
Accepted
2025-06-17 16:30:33
Documents
16
Period of Report
2025-06-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tennx_8k.htm   iXBRL 8-K 53458
2 EX-3.1 tennx_ex31.htm EX-3.1 9066
3 EX-3.2 tennx_ex32.htm EX-3.2 33517
  Complete submission text file 0001654954-25-007104.txt   229552

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tennx-20250611.xsd EX-101.SCH 5897
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tennx-20250611_lab.xml EX-101.LAB 15214
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tennx-20250611_cal.xml EX-101.CAL 911
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tennx-20250611_pre.xml EX-101.PRE 9653
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tennx-20250611_def.xml EX-101.DEF 2112
18 EXTRACTED XBRL INSTANCE DOCUMENT tennx_8k_htm.xml XML 4037
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 251053743
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)